Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
ParticipantDT
Deep Track Capital
Activity from announced rounds
Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.
Recorded funding activity
Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.
- Rounds participated in
- 5
- Confirmed lead rounds
- 1 2 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $426M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionSuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
ParticipantTriveni Bio
Develops novel antibody treatments for immunological and inflammatory disorders
$65MSeries C
Role not disclosedTerremoto Biosciences
Develops highly targeted, small molecule medicines for cancer and rare diseases
$108MSeries C
Role not disclosedAmbrosia Biosciences
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
$100MSeries B
Lead